“…Inhibition of protein kinases A and C and of protein tyrosine kinase (PTK) has been described (Steglich, 1989;Toullec et al, 1991;Lakatosh et al, 2002). These bisindolylimides and their derivatives are, in contrast to indolo[2,3-a] carbazoles, not bridged at their indole-2-positions and show different biological activies (Routier et al, 2002;Caballero et al, 2003;Lobo and Prabhakar, 2002;Slater et al, 2001). Therefore, they are also named secoindolocarbazoles (Link et al, 1995).…”